Lv4
590 积分 2024-09-16 加入
FGF21 reverses MASH through coordinated actions on the CNS and liver
5小时前
待确认
Hydronidone Alleviates Metabolic Dysfunction‐Associated Fatty Liver Disease by Inhibiting CD36 Expression
12天前
已完结
The expanding landscape of GLP-1 medicines
4个月前
已完结
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity
5个月前
已完结
RYK is a GPNMB receptor that drives MASH
5个月前
已完结
Amylin receptor subunit interactions are modulated by agonists and determine signaling
7个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
7个月前
已完结
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
9个月前
已完结
Obesity drugs aren’t always forever. What happens when you quit?
9个月前
已完结
FRI-383 Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
10个月前
已关闭
皖公网安备34019202002308
